Zepbound
$700.00
Zepbound is the weight-loss-specific brand name for tirzepatide, the same active ingredient in Mounjaro. Approved by the FDA in November 2023, it’s the first dual GIP/GLP-1 receptor agonist specifically indicated for chronic weight management.
Key Differences from Mounjaro:
-
Same molecule, different branding/packaging
-
Approved specifically for obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions
-
Higher maximum dose (15mg vs Mounjaro’s 10mg for diabetes)
How It Works: Triple-Action Weight Loss
-
Brain (Appetite Control):
-
Reduces hunger signals by 40-60%
-
Decreases food cravings, especially for high-fat foods
-
-
Gut (Digestion):
-
Slows gastric emptying by 55-65%
-
Increases satiety hormones (PYY, GLP-1)
-
-
Fat Cells (Metabolism):
-
Improves insulin sensitivity
-
Promotes healthier fat distribution
-
Proven Results: Clinical Trial Data
| Trial | Duration | Average Weight Loss | Key Finding |
|---|---|---|---|
| SURMOUNT-1 | 72 weeks | 15-21% | 37% lost ≥25% body weight |
| SURMOUNT-2 | 72 weeks | 16-22% | Superior to semaglutide |
| SURMOUNT-3 | 12 wk lead-in | 24.3% | With intensive lifestyle intervention |
-
Same molecule, different branding/packaging
-
Approved specifically for obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions
-
Higher maximum dose (15mg vs Mounjaro’s 10mg for diabetes)
We offer complimentary express shipping.
Free returns are available worldwide. If your item is eligible for return, you have 30 days from the date you receive your order to follow this procedure.
See delivery and returns for more information.
Shop The Look
